Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? insights from post-hoc analysis of EXSCEL

Cardiovascular outcome trials with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown that they have cardiovascular benefits [1]. Likely mechanisms are multifactorial (e.g., weight loss) [2 –4] and may include a direct GLP-1 RA effect on the vasculature [5–8]. GLP-1 receptors are expressed in the human vasculature [9–11], but it is uncertain whether they are involved in mediating the vascular actions of GLP-1 RAs [6,8] Proposed mediators underlying GLP-1 RA vascular actions inclu de nitric oxide, hydrogen sulfide, and potassium channels, particularly KATP channels [7,12,13] as well as the endothelin pathway [9].
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research